FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Michael Jacobs

Research Profile

Procedures

Microbial Sensitivity Tests

Living Beings

Chemicals & Drugs

Physiology

Disorders

Pneumococcal Infections

Co-author Network

Publications

TOP 3
Karem C Harth; Michael R Jacobs; James M Anderson; Jeffrey A Blatnik; Farhad Zeinali; Michael J Rosen
Effect of surgical wound classification on biologic graft performance in complex hernia repair: an experimental study.
Jeffrey A Blatnik; Yue Gao; Michael R Jacobs; David M Krpata; Yuri W Novitsky; Michael J Rosen
In vivo analysis of the morphologic characteristics of synthetic mesh to resist MRSA adherence.
Liem Nguyen; Michael R Jacobs
Counterattacking drug-resistant tuberculosis: molecular strategies and future directions.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Michael Jacobs (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Karem C Harth; Michael R Jacobs; James M Anderson; Jeffrey A Blatnik; Farhad Zeinali; Michael J Rosen
Effect of surgical wound classification on biologic graft performance in complex hernia repair: an experimental study.
Surgery 2013;153(4):481-92.
2012: Jeffrey A Blatnik; Yue Gao; Michael R Jacobs; David M Krpata; Yuri W Novitsky; Michael J Rosen
In vivo analysis of the morphologic characteristics of synthetic mesh to resist MRSA adherence.
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2012;16(11):2139-44.
2012: Liem Nguyen; Michael R Jacobs
Counterattacking drug-resistant tuberculosis: molecular strategies and future directions.
Expert review of anti-infective therapy 2012;10(9):959-61.
2012: Divya Rana; Dennis M Super; Nazha Abughali; Michael R Jacobs; Deepak Kumar; Mary L Kumar
Staphylococcus aureus, including community-acquired methicillin-resistant S. aureus, in a level III NICU: 2001 to 2008.
American journal of perinatology 2012;29(6):401-8.
2012: Roberto A Viau; David F Briceño; Michael Dul; Richard Grossberg; Andrea Hujer; Kristine M Hujer; Michael R Jacobs; Steven H Marshall; Federico Perez; Philip Toltzis; Robert A Bonomo
"Silent" dissemination of Klebsiella pneumoniae isolates bearing K. pneumoniae carbapenemase in a long-term care facility for children and young adults in Northeast Ohio.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2012;54(9):1314-21.
2012: Brooke K Decker; David J Ecker; Mark W Eshoo; Wondwossen A Gebreyes; Geraldine S Hall; Andrea Hujer; Kristine M Hujer; Michael R Jacobs; Christian Massire; Federico Perez; Philip N Rather; Scott T Zoll; Robert A Bonomo
Longitudinal analysis of the temporal evolution of Acinetobacter baumannii strains in Ohio, USA, by using rapid automated typing methods.
PloS one 2012;7(4):e33443.
2011: K C Harth; Michael R Jacobs; Saralee Bajaksouzian; J A Blatnik; A-M Broome; F Zeinali; Michael J Rosen
Bacterial clearance of biologic grafts used in hernia repair: an experimental study.
Surgical endoscopy 2011;25(7):2224-9.
2011: Andrea Endimiani; Kristine M Hujer; Andrea Hujer; Sebastian Kurz; Michael R Jacobs; David S Perlin; Robert A Bonomo
Are we ready for novel detection methods to treat respiratory pathogens in hospital-acquired pneumonia?
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2011;52 Suppl 4():S373-83.
2011: Michael R Jacobs; Saralee Bajaksouzian; Caryn E Good; Michelle M Butler; John D Williams; Norton P Peet; Terry L Bowlin; Andrea Endimiani; Robert A Bonomo
Novel bis-indole agents active against multidrug-resistant Acinetobacter baumannii.
Diagnostic microbiology and infectious disease 2011;69(1):114-6.
2010: Amy Ray; Federico Perez; Amanda M Beltramini; Marta Jakubowycz; Patricia Dimick; Michael R Jacobs; Kathy Roman; Robert A Bonomo; Robert A Salata
Use of vaporized hydrogen peroxide decontamination during an outbreak of multidrug-resistant Acinetobacter baumannii infection at a long-term acute care hospital.
Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America 2010;31(12):1236-41.
2010: Sadao Jinno; Barbara M Gripshover; Tracy L Lemonovich; James M Anderson; Michael R Jacobs
Histoplasma capsulatum prosthetic valve endocarditis with negative fungal blood cultures and negative histoplasma antigen assay in an immunocompetent patient.
Journal of clinical microbiology 2010;48(12):4664-6.
2010: Andrea Endimiani; Federico Perez; Saralee Bajaksouzian; Anne Windau; Caryn E Good; Yuvraj Choudhary; Andrea M Hujer; Christopher R Bethel; Robert A Bonomo; Michael R Jacobs
Evaluation of updated interpretative criteria for categorizing Klebsiella pneumoniae with reduced carbapenem susceptibility.
Journal of clinical microbiology 2010;48(12):4417-25.
2010: Karem C Harth; Michael J Rosen; Thimma R Thatiparti; Michael R Jacobs; Ihab Halaweish; Saralee Bajaksouzian; Joseph Furlan; Horst A von Recum
Antibiotic-releasing mesh coating to reduce prosthetic sepsis: an in vivo study.
The Journal of surgical research 2010;163(2):337-43.
2010: Moses L Joloba; Benson R Kidenya; David P Kateete; Fred A Katabazi; Julian K Muwanguzi; Benon B Asiimwe; Simon P Alarakol; Jessica L Nakavuma; Saralee Bajaksouzian; Anne Windau; Michael R Jacobs
Comparison of transformation frequencies among selected Streptococcus pneumoniae serotypes.
International journal of antimicrobial agents 2010;36(2):124-8.
2010: Michael R Jacobs; Caryn E Good; Anne Windau; Saralee Bajaksouzian; Donald Biek; Ian A Critchley; Helio S Sader; Ronald N Jones
Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
Antimicrobial agents and chemotherapy 2010;54(6):2716-9.
2010: Michael R Jacobs; Ron Dagan; Saralee Bajaksouzian; Anne Windau; Nurith Porat
Validation of factor 6d antiserum for serotyping Streptococcus pneumoniae serotype 6C.
Journal of clinical microbiology 2010;48(4):1456-7.
2010: Elizabeth L Palavecino; Roslyn A Yomtovian; Michael R Jacobs
Bacterial contamination of platelets.
Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis 2010;42(1):71-82.
2010: Andrea Endimiani; Gopi Patel; Kristine M Hujer; Mahesh Swaminathan; Federico Perez; Louis B Rice; Michael R Jacobs; Robert A Bonomo
In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin.
Antimicrobial agents and chemotherapy 2010;54(1):526-9.
2009: Loretta Szczotka-Flynn; Saralee Bajaksouzian; Michael R Jacobs; Alfred Rimm
Risk factors for contact lens bacterial contamination during continuous wear.
Optometry and vision science : official publication of the American Academy of Optometry 2009;86(11):1216-26.
2009: Mark D Adams; Gabrielle C Nickel; Saralee Bajaksouzian; Heather Lavender; A Rekha Murthy; Michael R Jacobs; Robert A Bonomo
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.
Antimicrobial agents and chemotherapy 2009;53(9):3628-34.
2009: Fengchan Han; Heping Yu; Cong Tian; Shengli Li; Michael R Jacobs; Cindy Benedict-Alderfer; Qing Y Zheng
Role for Toll-like receptor 2 in the immune response to Streptococcus pneumoniae infection in mouse otitis media.
Infection and immunity 2009;77(7):3100-8.
2009: Michael R Jacobs; Saralee Bajaksouzian; Robert A Bonomo; Caryn E Good; Anne Windau; Andrea Hujer; Christian Massire; Rachael Melton; Lawrence B Blyn; David J Ecker; Rangarajan Sampath
Occurrence, distribution, and origins of Streptococcus pneumoniae Serotype 6C, a recently recognized serotype.
Journal of clinical microbiology 2009;47(1):64-72.
2008: Michael R Jacobs; Caryn E Good; Saralee Bajaksouzian; Anne Windau
Emergence of Streptococcus pneumoniae serotypes 19A, 6C, and 22F and serogroup 15 in Cleveland, Ohio, in relation to introduction of the protein-conjugated pneumococcal vaccine.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2008;47(11):1388-95.
2008: Michael R Jacobs
Antimicrobial-resistant Streptococcus pneumoniae: trends and management.
Expert review of anti-infective therapy 2008;6(5):619-35.
2008: Michael R Jacobs; Caryn E Good; Hillard M Lazarus; Roslyn Yomtovian
Relationship between bacterial load, species virulence, and transfusion reaction with transfusion of bacterially contaminated platelets.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2008;46(8):1214-20.
2008: Michael R Jacobs; Caryn E Good; Bernard W. Beall; Saralee Bajaksouzian; Anne Windau; Cynthia G Whitney
Changes in serotypes and antimicrobial susceptibility of invasive Streptococcus pneumoniae strains in Cleveland: a quarter century of experience.
Journal of clinical microbiology 2008;46(3):982-90.
2007: Michael R Jacobs
Retapamulin: a semisynthetic pleuromutilin compound for topical treatment of skin infections in adults and children.
Future microbiology 2007;2(6):591-600.
2007: Michael R Jacobs
Combating resistance: application of the emerging science of pharmacokinetics and pharmacodynamics.
International journal of antimicrobial agents 2007;30 Suppl 2():S122-6.
2007: Michael R Jacobs; Ronald Jones; Philip A Giordano
Oral beta-lactams applied to uncomplicated infections of skin and skin structures.
Diagnostic microbiology and infectious disease 2007;57(3 Suppl):55S-65S.
2007: Samantha Easley; Roslyn Yomtovian; Patricia Sullivan; Michael R Jacobs
Development of proficiency testing for detection of bacterial contamination of platelet products.
Transfusion 2007;47(2):251-5.
2007: Michael R Jacobs; Caryn E Good; Tom Sellner; Saralee Bajaksouzian; Anne Windau; Jack B Anon
Nasopharyngeal carriage of respiratory pathogens in children undergoing pressure equalization tube placement in the era of pneumococcal protein conjugate vaccine use.
The Laryngoscope 2007;117(2):295-8.
2007: David B Blossom; S M Cordeiro; Saralee Bajaksouzian; Moses L Joloba; Cissy Kityo; Christopher Curtis Whalen; Robert A Salata; Michael R Jacobs
Characterization of penicillin intermediate serotypes of Streptococcus pneumoniae carried by human immunodeficiency virus-infected adults and healthy children in Uganda.
Microbial drug resistance (Larchmont, N.Y.) 2007;13(1):21-8.
2006: David B Blossom; Grace Namayanja-Kaye; Joan Nankya-Mutyoba; John B Mukasa; Henry Bakka; Sandra Rwambuya; Anne Windau; Saralee Bajaksouzian; Courtney J Walker; Moses L Joloba; Cissy Kityo; Peter Mugyenyi; Christopher Curtis Whalen; Michael R Jacobs; Robert A Salata
Oropharyngeal colonization by Streptococcus pneumoniae among HIV-infected adults in Uganda: assessing prevalence and antimicrobial susceptibility.
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2006;10(6):458-64.
2006: Michael R Jacobs; Peter C Appelbaum
Nadifloxacin: a quinolone for topical treatment of skin infections and potential for systemic use of its active isomer, WCK 771.
Expert opinion on pharmacotherapy 2006;7(14):1957-66.
2006: Roslyn Yomtovian; Elizabeth Palavecino; Alden H Dysktra; Katharine A Downes; Anne M Morrissey; Saralee Bajaksouzian; Marcella A Pokorny; Hillard M Lazarus; Michael R Jacobs
Evolution of surveillance methods for detection of bacterial contamination of platelets in a university hospital, 1991 through 2004.
Transfusion 2006;46(5):719-30.
2006: Glenn A Pankuch; Gengrong Lin; Dianne B Hoellman; Caryn E Good; Michael R Jacobs; Peter C Appelbaum
Activity of retapamulin against Streptococcus pyogenes and Staphylococcus aureus evaluated by agar dilution, microdilution, E-test, and disk diffusion methodologies.
Antimicrobial agents and chemotherapy 2006;50(5):1727-30.
2006: Elizabeth Palavecino; Roslyn Yomtovian; Michael R Jacobs
Detecting bacterial contamination in platelet products.
Clinical laboratory 2006;52(9-10):443-56.
2006: Philip Toltzis; Michael Dul; Mary Ann O'Riordan; Michael R Jacobs; Jeffrey Blumer
Serogroup 19 pneumococci containing both mef and erm macrolide resistance determinants in an American city.
The Pediatric infectious disease journal 2006;25(1):19-24.
2005: David Felmingham; Anthony R White; Michael R Jacobs; Peter C Appelbaum; James Poupard; Linda A Miller; Reuben N Grüneberg
The Alexander Project: the benefits from a decade of surveillance.
The Journal of antimicrobial chemotherapy 2005;56 Suppl 2():ii3-ii21.
2005: Peter C Appelbaum; Michael R Jacobs
Recently approved and investigational antibiotics for treatment of severe infections caused by Gram-positive bacteria.
Current opinion in microbiology 2005;8(5):510-7.
2005: Philip Toltzis; Michael R Jacobs
The epidemiology of childhood pneumococcal disease in the United States in the era of conjugate vaccine use.
Infectious disease clinics of North America 2005;19(3):629-45.
2005: Noël de Souza; Shrikant V Gupte; Prasad K Deshpande; Vijaya N Desai; Satish B Bhawsar; Ravindra Yeole; Milind C Shukla; Jacob Strahilevitz; David C Hooper; Bülent Bozdogan; Peter C Appelbaum; Michael R Jacobs; Nitin Shetty; Mahesh V Patel; Rasendrakumar Jha; Habil F Khorakiwala
A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
Journal of medicinal chemistry 2005;48(16):5232-42.
2005: Michael R Jacobs
Antimicrobial Agents and Resistance--Fifth International Symposium. Antifungal agents and novel vaccines.
IDrugs : the investigational drugs journal 2005;8(7):547-50.
2005: Michael R Jacobs
Antimicrobial Agents And Resistance--Fifth International Symposium.
IDrugs : the investigational drugs journal 2005;8(7):542-6.
2005: Michael R Jacobs
Extended release amoxicillin/clavulanate: optimizing a product for respiratory infections based on pharmacodynamic principles.
Expert review of anti-infective therapy 2005;3(3):353-60.
2005: Dennis O Gor; Xuedong Ding; David E Briles; Michael R Jacobs; Neil S Greenspan
Relationship between surface accessibility for PpmA, PsaA, and PspA and antibody-mediated immunity to systemic infection by Streptococcus pneumoniae.
Infection and immunity 2005;73(3):1304-12.
2005: Michael R Jacobs; Saralee Bajaksouzian; Anne Windau; Elizabeth Palavecino; Roslyn Yomtovian
Evaluation of the Scansystem method for detection of bacterially contaminated platelets.
Transfusion 2005;45(2):265-9.
2005: Peter C Appelbaum; Glenn A Pankuch; Bülent Bozdogan; Gengrong Lin; Michael R Jacobs; Mahesh V Patel; S V Gupte; M A Jafri; Noël de Souza; Habil F Khorakiwala
Activity of the new quinolone WCK 771 against pneumococci.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2005;11(1):9-14.
2004: Mahesh V Patel; Noël de Souza; Shrikant V Gupte; Mohammad A Jafri; Sachin S Bhagwat; Yati Chugh; Habil F Khorakiwala; Michael R Jacobs; Peter C Appelbaum
Antistaphylococcal activity of WCK 771, a tricyclic fluoroquinolone, in animal infection models.
Antimicrobial agents and chemotherapy 2004;48(12):4754-61.
2004: Klaudia Kosowska; Kim Credito; Glenn A Pankuch; Dianne B Hoellman; Gengrong Lin; Catherine Clark; Bonifacio Dewasse; Pamela McGhee; Michael R Jacobs; Peter C Appelbaum
Activities of two novel macrolides, GW 773546 and GW 708408, compared with those of telithromycin, erythromycin, azithromycin, and clarithromycin against Haemophilus influenzae.
Antimicrobial agents and chemotherapy 2004;48(11):4113-9.
2004: Vlatka Matic; Klaudia Kosowska; Bülent Bozdogan; Linda M Kelly; Kathy Smith; Lois M Ednie; Gengrong Lin; Kim Credito; Catherine L Clark; Pamela McGhee; Glenn A Pankuch; Michael R Jacobs; Peter C Appelbaum
Antipneumococcal activities of two novel macrolides, GW 773546 and GW 708408, compared with those of erythromycin, azithromycin, clarithromycin, clindamycin, and telithromycin.
Antimicrobial agents and chemotherapy 2004;48(11):4103-12.
2004: Laura M Koeth; Michael R Jacobs; Caryn E Good; Saralee Bajaksouzian; Anne Windau; Charles Jakielaszek; Kay A Saunders
Comparative in vitro activity of a pharmacokinetically enhanced oral formulation of amoxicillin/clavulanic acid (2000/125 mg twice daily) against 9172 respiratory isolates collected worldwide in 2000.
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2004;8(6):362-73.
2004: K Kosowska; Michael R Jacobs; Saralee Bajaksouzian; Laura M Koeth; Peter C Appelbaum
Alterations of penicillin-binding proteins 1A, 2X, and 2B in Streptococcus pneumoniae isolates for which amoxicillin MICs are higher than penicillin MICs.
Antimicrobial agents and chemotherapy 2004;48(10):4020-2.
2004: Bülent Bozdogan; Tatiana Bogdanovich; Klaudia Kosowska; Michael R Jacobs; Peter C Appelbaum
Macrolide resistance in Streptococcus pneumoniae: clonality and mechanisms of resistance in 24 countries.
Current drug targets. Infectious disorders 2004;4(3):169-76.
2004: Michael R Jacobs; Saralee Bajaksouzian; Anne Windau; Peter C Appelbaum; Mahesh V Patel; Shrikant V Gupte; Sachin S Bhagwat; Noël de Souza; Habil F Khorakiwala
In vitro activity of the new quinolone WCK 771 against staphylococci.
Antimicrobial agents and chemotherapy 2004;48(9):3338-42.
2004: Michael R Jacobs
Streptococcus pneumoniae: epidemiology and patterns of resistance.
The American journal of medicine 2004;117 Suppl 3A():3S-15S.
2004: Mihaela Peric; Michael R Jacobs; Peter C Appelbaum
Antianaerobic activity of a novel fluoroquinolone, WCK 771, compared to those of nine other agents.
Antimicrobial agents and chemotherapy 2004;48(8):3188-92.
2004: Michael R Jacobs; Saralee Bajaksouzian; Anne Windau; Caryn E Good; Gengrong Lin; Glenn A Pankuch; Peter C Appelbaum
Susceptibility of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis to 17 oral antimicrobial agents based on pharmacodynamic parameters: 1998-2001 U S Surveillance Study.
Clinics in laboratory medicine 2004;24(2):503-30.
2004: Michael R Jacobs; Jack B Anon; Peter C Appelbaum
Mechanisms of resistance among respiratory tract pathogens.
Clinics in laboratory medicine 2004;24(2):419-53.
2004: Catherine Clark; Klaudia Kosowska; Bülent Bozdogan; Kim Credito; Bonifacio Dewasse; Pamela McGhee; Michael R Jacobs; Peter C Appelbaum
In vitro selection of resistance in haemophilus influenzae by 4 quinolones and 5 beta-lactams.
Diagnostic microbiology and infectious disease 2004;49(1):31-6.
2004: Laura M Koeth; D Felmingham; Michael R Jacobs; F Rossi
Antimicrobial resistance of Streptococcus pneumoniae and Haemophilus influenzae in Sao Paulo, Brazil from 1996 to 2000.
International journal of antimicrobial agents 2004;23(4):356-61.
2004: Michael R Jacobs
Building in efficacy: developing solutions to combat drug-resistant S. pneumoniae.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2004;10 Suppl 2():18-27.
2004: Michael R Jacobs
Fluoroquinolones as chemotherapeutics against mycobacterial infections.
Current pharmaceutical design 2004;10(26):3213-20.
2004: Michael R Jacobs; Ron Dagan
Antimicrobial resistance among pediatric respiratory tract infections: clinical challenges.
Seminars in pediatric infectious diseases 2004;15(1):5-20.
2003: Frederick A Browne; Bülent Bozdogan; Catherine Clark; Linda M Kelly; Lois M Ednie; Klaudia Kosowska; Bonifacio Dewasse; Michael R Jacobs; Peter C Appelbaum
Antipneumococcal activity of DK-507k, a new quinolone, compared with the activities of 10 other agents.
Antimicrobial agents and chemotherapy 2003;47(12):3815-24.
2003: Vlatka Matic; Bülent Bozdogan; Michael R Jacobs; Kimiko Ubukata; Peter C Appelbaum
Contribution of beta-lactamase and PBP amino acid substitutions to amoxicillin/clavulanate resistance in beta-lactamase-positive, amoxicillin/clavulanate-resistant Haemophilus influenzae.
The Journal of antimicrobial chemotherapy 2003;52(6):1018-21.
2003: Michael R Jacobs; Saralee Bajaksouzian; Peter C Appelbaum
Telithromycin post-antibiotic and post-antibiotic sub-MIC effects for 10 Gram-positive cocci.
The Journal of antimicrobial chemotherapy 2003;52(5):809-12.
2003: Glenn A Pankuch; Linda M Kelly; Gengrong Lin; André Bryskier; Catherine Couturier; Michael R Jacobs; Peter C Appelbaum
Activities of a new oral streptogramin, XRP 2868, compared to those of other agents against Streptococcus pneumoniae and haemophilus species.
Antimicrobial agents and chemotherapy 2003;47(10):3270-4.
2003: Glenn A Pankuch; Michael R Jacobs; Peter C Appelbaum
Postantibiotic effects of daptomycin against 14 staphylococcal and pneumococcal clinical isolates.
Antimicrobial agents and chemotherapy 2003;47(9):3012-4.
2003: Michael R Jacobs
Worldwide trends in antimicrobial resistance among common respiratory tract pathogens in children.
The Pediatric infectious disease journal 2003;22(8 Suppl):S109-19.
2003: Michael R Jacobs; David Felmingham; Peter C Appelbaum; Reuben N Grüneberg
The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents.
The Journal of antimicrobial chemotherapy 2003;52(2):229-46.
2003: Bülent Bozdogan; Peter C Appelbaum; Linda M Kelly; Dianne B Hoellman; Arjana Tambic Andrasevic; Liga Drukalska; Waleria Hryniewicz; Helena Hupkova; Michael R Jacobs; Jana Kolman; M Konkoly-Thege; Jolanta Miciuleviciene; Marina Pana; Lena Setchanova; Jan Trupl; Pavla Urbaskova
Activity of telithromycin compared with seven other agents against 1039 Streptococcus pyogenes pediatric isolates from ten centers in central and eastern Europe.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2003;9(7):741-5.
2003: Bülent Bozdogan; Peter C Appelbaum; Linda M Kelly; Dianne B Hoellman; Arjana Tambic Andrasevic; Liga Drukalska; Waleria Hryniewicz; Helena Hupkova; Michael R Jacobs; Jana Kolman; M Konkoly-Thege; Jolanta Miciuleviciene; Marina Pana; Lena Setchanova; Jan Trupl; Pavla Urbaskova
Activity of telithromycin and seven other agents against 1034 pediatric Streptococcus pneumoniae isolates from ten central and eastern European centers.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2003;9(7):653-61.
2003: Mendel E Singer; Ian Harding; Michael R Jacobs; Dena H Jaffe
Impact of antimicrobial resistance on health outcomes in the out-patient treatment of adult community-acquired pneumonia: a probability model.
The Journal of antimicrobial chemotherapy 2003;51(5):1269-82.
2003: Kim Credito; Michael R Jacobs; Peter C Appelbaum
Time-kill studies of the antianaerobe activity of garenoxacin compared with those of nine other agents.
Antimicrobial agents and chemotherapy 2003;47(4):1399-402.
2003: Michael R Jacobs
How can we predict bacterial eradication?
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2003;7 Suppl 1():S13-20.
2003: Dianne B Hoellman; Gengrong Lin; Lois M Ednie; Ashok Rattan; Michael R Jacobs; Peter C Appelbaum
Antipneumococcal and antistaphylococcal activities of ranbezolid (RBX 7644), a new oxazolidinone, compared to those of other agents.
Antimicrobial agents and chemotherapy 2003;47(3):1148-50.
2003: Lois M Ednie; Ashok Rattan; Michael R Jacobs; Peter C Appelbaum
Antianaerobe activity of RBX 7644 (ranbezolid), a new oxazolidinone, compared with those of eight other agents.
Antimicrobial agents and chemotherapy 2003;47(3):1143-7.
2003: Glenn A Pankuch; Michael R Jacobs; Peter C Appelbaum
Postantibiotic effects of garenoxacin (BMS-284756) against 12 gram-positive or -negative organisms.
Antimicrobial agents and chemotherapy 2003;47(3):1140-2.
2003: Mihaela Peric; Bülent Bozdogan; Michael R Jacobs; Peter C Appelbaum
Effects of an efflux mechanism and ribosomal mutations on macrolide susceptibility of Haemophilus influenzae clinical isolates.
Antimicrobial agents and chemotherapy 2003;47(3):1017-22.
2003: Glenn A Pankuch; Michael R Jacobs; Peter C Appelbaum
Bactericidal activity of daptomycin against Streptococcus pneumoniae compared with eight other antimicrobials.
The Journal of antimicrobial chemotherapy 2003;51(2):443-6.
2002: Dianne B Hoellman; Linda M Kelly; Michael R Jacobs; Peter C Appelbaum
In vitro anti-anaerobic activity of the cephalosporin derivative RWJ 54428, compared to seven other compounds.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2002;8(12):814-22.
2002: Michael R Jacobs; Laura M Koeth; Peter C Appelbaum
Use of appropriate breakpoints in antimicrobial surveillance studies.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2002;35(11):1446-8; author reply 1448-9.
2002: Michael R Jacobs; Saralee Bajaksouzian; Anne Windau; Peter C Appelbaum; Gengrong Lin; David Felmingham; Christine Dencer; Laura M Koeth; Mendel E Singer; Caryn E Good
Effects of various test media on the activities of 21 antimicrobial agents against Haemophilus influenzae.
Journal of clinical microbiology 2002;40(9):3269-76.
2002: Catherine Clark; Bülent Bozdogan; Mihaela Peric; Bonifacio Dewasse; Michael R Jacobs; Peter C Appelbaum
In vitro selection of resistance in Haemophilus influenzae by amoxicillin-clavulanate, cefpodoxime, cefprozil, azithromycin, and clarithromycin.
Antimicrobial agents and chemotherapy 2002;46(9):2956-62.
2002: Elizabeth Palavecino; I Riedel; C Duran; Saralee Bajaksouzian; Moses L Joloba; T Davies; Peter C Appelbaum; Michael R Jacobs
Macrolide resistance phenotypes in Streptococcus pneumoniae in Santiago, Chile.
International journal of antimicrobial agents 2002;20(2):108-12.
2002: Frederick A Browne; Cathy Clark; Bülent Bozdogan; Bonifacio Dewasse; Michael R Jacobs; Peter C Appelbaum
Single and multi-step resistance selection study in Streptococcus pneumoniae comparing ceftriaxone with levofloxacin, gatifloxacin and moxifloxacin.
International journal of antimicrobial agents 2002;20(2):93-9.
2002: Michael R Jacobs
Prevention of otitis media: role of pneumococcal conjugate vaccines in reducing incidence and antibiotic resistance.
The Journal of pediatrics 2002;141(2):287-93.
2002: Lois M Ednie; Michael R Jacobs; Peter C Appelbaum
Anti-anaerobic activity of AZD2563, a new oxazolidinone, compared with eight other agents.
The Journal of antimicrobial chemotherapy 2002;50(1):101-5.
2002: Catherine L Clark; Kensuke Nagai; Bonifacio Dewasse; Glenn A Pankuch; Lois M Ednie; Michael R Jacobs; Peter C Appelbaum
Activity of cefditoren against respiratory pathogens.
The Journal of antimicrobial chemotherapy 2002;50(1):33-41.
2002: Catherine L Clark; Kensuke Nagai; Todd A Davies; Bülent Bozdogan; Bonifacio Dewasse; Michael R Jacobs; Peter C Appelbaum
Single- and multistep selection study of the antipneumococcal activity of BMS-284756 compared to ciprofloxacin, levofloxacin, trovafloxacin and moxifloxacin.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2002;8(6):373-80.
2002: Kensuke Nagai; Todd A Davies; Michael R Jacobs; Peter C Appelbaum
Effects of amino acid alterations in penicillin-binding proteins (PBPs) 1a, 2b, and 2x on PBP affinities of penicillin, ampicillin, amoxicillin, cefditoren, cefuroxime, cefprozil, and cefaclor in 18 clinical isolates of penicillin-susceptible, -intermediate, and -resistant pneumococci.
Antimicrobial agents and chemotherapy 2002;46(5):1273-80.
2002: Evan J Goodman; Michael R Jacobs; Saralee Bajaksouzian; Anne Windau; J P Dagirmanjian
Clinically significant concentrations of local anesthetics inhibit Staphylococcus aureus in vitro.
International journal of obstetric anesthesia 2002;11(2):95-9.
2002: Kensuke Nagai; Peter C Appelbaum; Todd A Davies; Linda M Kelly; Dianne B Hoellman; Arjana Tambic Andrasevic; Liga Drukalska; Waleria Hryniewicz; Michael R Jacobs; Jana Kolman; Jolanta Miciuleviciene; Marina Pana; Lena Setchanova; Marianne Konkoly Thege; Helena Hupkova; Jan Trupl; Pavla Urbaskova
Susceptibility to telithromycin in 1,011 Streptococcus pyogenes isolates from 10 central and Eastern European countries.
Antimicrobial agents and chemotherapy 2002;46(2):546-9.
2002: Kensuke Nagai; Peter C Appelbaum; Todd A Davies; Linda M Kelly; Dianne B Hoellman; Arjana Tambic Andrasevic; Liga Drukalska; Waleria Hryniewicz; Michael R Jacobs; Jana Kolman; Jolanta Miciuleviciene; Marina Pana; Lena Setchanova; Marianne Konkoly Thege; Helena Hupkova; Jan Trupl; Pavla Urbaskova
Susceptibilities to telithromycin and six other agents and prevalence of macrolide resistance due to L4 ribosomal protein mutation among 992 Pneumococci from 10 central and Eastern European countries.
Antimicrobial agents and chemotherapy 2002;46(2):371-7.
2002: Laura M Koeth; Michael R Jacobs; Saralee Bajaksouzian; Anne Zilles; Gengrong Lin; Peter C Appelbaum
Comparative in vitro activity of gemifloxacin to other fluoroquinolones and non-quinolone agents against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the United States in 1999-2000.
International journal of antimicrobial agents 2002;19(1):33-7.
2002: Glenn A Pankuch; Kensuke Nagai; Todd A Davies; Michael R Jacobs; Peter C Appelbaum
Antipneumococcal activity of BMS 284756 compared to those of six other agents.
Antimicrobial agents and chemotherapy 2002;46(1):251-4.
2002: Dianne B Hoellman; Linda M Kelly; Kim Credito; Lauren Anthony; Lois M Ednie; Michael R Jacobs; Peter C Appelbaum
In vitro antianaerobic activity of ertapenem (MK-0826) compared to seven other compounds.
Antimicrobial agents and chemotherapy 2002;46(1):220-4.
2002: Glenn A Pankuch; Todd A Davies; Michael R Jacobs; Peter C Appelbaum
Antipneumococcal activity of ertapenem (MK-0826) compared to those of other agents.
Antimicrobial agents and chemotherapy 2002;46(1):42-6.
2001: K Nagai; Y Shibasaki; K Hasegawa; Todd A Davies; Michael R Jacobs; K Ubukata; Peter C Appelbaum
Evaluation of PCR primers to screen for Streptococcus pneumoniae isolates and beta-lactam resistance, and to detect common macrolide resistance determinants.
The Journal of antimicrobial chemotherapy 2001;48(6):915-8.
2001: Michael R Jacobs
Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2001;7(11):589-96.
2001: Michael R Jacobs; Elizabeth Palavecino; Roslyn Yomtovian
Don't bug me: the problem of bacterial contamination of blood components--challenges and solutions.
Transfusion 2001;41(11):1331-4.
2001: Moses L Joloba; Anne Windau; Saralee Bajaksouzian; Peter C Appelbaum; W P Hausdorff; Michael R Jacobs
Pneumococcal conjugate vaccine serotypes of Streptococcus pneumoniae isolates and the antimicrobial susceptibility of such isolates in children with otitis media.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2001;33(9):1489-94.
2001: K Nagai; Todd A Davies; Bonifacio Dewasse; Michael R Jacobs; Peter C Appelbaum
Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae.
The Journal of antimicrobial chemotherapy 2001;48(3):365-74.
2001: Moses L Joloba; Saralee Bajaksouzian; Elizabeth Palavecino; Christopher Curtis Whalen; Michael R Jacobs
High prevalence of carriage of antibiotic-resistant Streptococcus pneumoniae in children in Kampala Uganda.
International journal of antimicrobial agents 2001;17(5):395-400.
2001: Michael R Jacobs; W Weinberg
Evidence-based guidelines for treatment of bacterial respiratory tract infections in the era of antibiotic resistance.
Managed care interface 2001;14(4):68-80.
2001: Dianne B Hoellman; Linda M Kelly; Michael R Jacobs; Peter C Appelbaum
Comparative antianaerobic activity of BMS 284756.
Antimicrobial agents and chemotherapy 2001;45(2):589-92.
2001: Elizabeth Palavecino; I Riedel; X Berrios; Saralee Bajaksouzian; D Johnson; E Kaplan; Michael R Jacobs
Prevalence and mechanisms of macrolide resistance in Streptococcus pyogenes in Santiago, Chile.
Antimicrobial agents and chemotherapy 2001;45(1):339-41.
2001: Kim Credito; Gengrong Lin; Glenn A Pankuch; Saralee Bajaksouzian; Michael R Jacobs; Peter C Appelbaum
Susceptibilities of Haemophilus influenzae and Moraxella catarrhalis to ABT-773 compared to their susceptibilities to 11 other agents.
Antimicrobial agents and chemotherapy 2001;45(1):67-72.
2000: K Nagai; Todd A Davies; Bonifacio Dewasse; Glenn A Pankuch; Michael R Jacobs; Peter C Appelbaum
In vitro development of resistance to ceftriaxone, cefprozil and azithromycin in Streptococcus pneumoniae.
The Journal of antimicrobial chemotherapy 2000;46(6):909-15.
2000: Kim Credito; Michael R Jacobs; Peter C Appelbaum
Anti-anaerobic activity of levofloxacin alone and combined with clindamycin and metronidazole.
Diagnostic microbiology and infectious disease 2000;38(3):181-3.
2000: Moses L Joloba; Saralee Bajaksouzian; Michael R Jacobs
Evaluation of Etest for susceptibility testing of Mycobacterium tuberculosis.
Journal of clinical microbiology 2000;38(10):3834-6.
2000: K Nagai; Todd A Davies; Glenn A Pankuch; Bonifacio Dewasse; Michael R Jacobs; Peter C Appelbaum
In vitro selection of resistance to clinafloxacin, ciprofloxacin, and trovafloxacin in Streptococcus pneumoniae.
Antimicrobial agents and chemotherapy 2000;44(10):2740-6.
2000: Michael R Jacobs; Peter C Appelbaum
Susceptibility of 1100 Streptococcus pneumoniae strains isolated in 1997 from seven Latin American and Caribbean countries. Laser Study Group.
International journal of antimicrobial agents 2000;16(1):17-24.
2000: Catherine L Clark; Linda M Kelly; Michael R Jacobs; Peter C Appelbaum
Activity of trovafloxacin, alone and in combination with other agents, against Enterobacteriaceae by time-kill analysis.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 2000;19(7):565-7.
2000: Todd A Davies; Lois M Ednie; D M Hoellman; Glenn A Pankuch; Michael R Jacobs; Peter C Appelbaum
Antipneumococcal activity of ABT-773 compared to those of 10 other agents.
Antimicrobial agents and chemotherapy 2000;44(7):1894-9.
2000: Lois M Ednie; Kim Credito; M Khantipong; Michael R Jacobs; Peter C Appelbaum
Synergic activity, for anaerobes, of trovafloxacin with clindamycin or metronidazole: chequerboard and time-kill methods.
The Journal of antimicrobial chemotherapy 2000;45(5):633-8.
2000: Lois M Ednie; Michael R Jacobs; Peter C Appelbaum
Activity of gemifloxacin, a new broad-spectrum quinolone, against 200 pneumococci by four different susceptibility testing methods.
The Journal of antimicrobial chemotherapy 2000;45(4):525-8.
2000: Todd A Davies; Linda M Kelly; Michael R Jacobs; Peter C Appelbaum
Antipneumococcal activity of telithromycin by agar dilution, microdilution, E test, and disk diffusion methodologies.
Journal of clinical microbiology 2000;38(4):1444-8.
2000: Dianne B Hoellman; Glenn A Pankuch; Michael R Jacobs; Peter C Appelbaum
Antipneumococcal activities of GAR-936 (a new glycylcycline) compared to those of nine other agents against penicillin-susceptible and -resistant pneumococci.
Antimicrobial agents and chemotherapy 2000;44(4):1085-8.
2000: Todd A Davies; Linda M Kelly; Dianne B Hoellman; Lois M Ednie; Catherine L Clark; Saralee Bajaksouzian; Michael R Jacobs; Peter C Appelbaum
Activities and postantibiotic effects of gemifloxacin compared to those of 11 other agents against Haemophilus influenzae and Moraxella catarrhalis.
Antimicrobial agents and chemotherapy 2000;44(3):633-9.
2000: Moses L Joloba; Christopher Curtis Whalen; D M Cave; Kathleen D Eisenach; John L Johnson; Alphonse Okwera; Anne M Morrissey; Saralee Bajaksouzian; J Feagin; Roy D Mugerwa; Jerrold Jay Ellner; Michael R Jacobs
Determination of drug susceptibility and DNA fingerprint patterns of clinical isolates of Mycobacterium tuberculosis from Kampala, Uganda.
East African medical journal 2000;77(2):111-5.
2000: Todd A Davies; Bonifacio Dewasse; Michael R Jacobs; Peter C Appelbaum
In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniae.
Antimicrobial agents and chemotherapy 2000;44(2):414-7.
2000: Todd A Davies; Linda M Kelly; Glenn A Pankuch; Kim Credito; Michael R Jacobs; Peter C Appelbaum
Antipneumococcal activities of gemifloxacin compared to those of nine other agents.
Antimicrobial agents and chemotherapy 2000;44(2):304-10.
2000: S K Spangler; S Bajaksouzian; Michael R Jacobs; Peter C Appelbaum
Postantibiotic effects of grepafloxacin compared to those of five other agents against 12 gram-positive and -negative bacteria.
Antimicrobial agents and chemotherapy 2000;44(1):186-9.
1999: Glenn A Pankuch; Michael R Jacobs; Peter C Appelbaum
Postantibiotic effects of gatifloxacin against gram-positive and -negative organisms.
Antimicrobial agents and chemotherapy 1999;43(10):2574-5.
1999: Linda M Kelly; Michael R Jacobs; Peter C Appelbaum
Comparison of agar dilution, microdilution, E-test, and disk diffusion methods for testing activity of cefditoren against Streptococcus pneumoniae.
Journal of clinical microbiology 1999;37(10):3296-9.
1999: Curtis J Donskey; John R Schreiber; Michael R Jacobs; R Shekar; Robert A Salata; S Gordon; Christopher Curtis Whalen; F Smith; Louis B Rice
A polyclonal outbreak of predominantly VanB vancomycin-resistant enterococci in northeast Ohio. Northeast Ohio Vancomycin-Resistant Enterococcus Surveillance Program.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1999;29(3):573-9.
1999: Glenn A Pankuch; Dianne B Hoellman; Michael R Jacobs; Peter C Appelbaum
Antipneumococcal activity of MEN 10700, a new penem, compared with other compounds, by MIC and time-kill kinetics.
The Journal of antimicrobial chemotherapy 1999;44(3):381-4.
1999: C L Clark; Michael R Jacobs; Peter C Appelbaum
Activities of clinafloxacin, alone and in combination with other compounds, against 45 gram-positive and -negative organisms for which clinafloxacin MICs are high.
Antimicrobial agents and chemotherapy 1999;43(9):2295-8.
1999: Kim Credito; Lois M Ednie; Michael R Jacobs; Peter C Appelbaum
Activity of telithromycin (HMR 3647) against anaerobic bacteria compared to those of eight other agents by time-kill methodology.
Antimicrobial agents and chemotherapy 1999;43(8):2027-31.
1999: Michael R Jacobs; Saralee Bajaksouzian; A Zilles; Gengrong Lin; Glenn A Pankuch; Peter C Appelbaum
Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. Surveillance study.
Antimicrobial agents and chemotherapy 1999;43(8):1901-8.
1999: Michael R Jacobs
Drug-resistant Streptococcus pneumoniae: rational antibiotic choices.
The American journal of medicine 1999;106(5A):19S-25S; discussion 48S-52S.
1999: Linda M Kelly; Michael R Jacobs; Peter C Appelbaum
Comparison of agar dilution, microdilution, Etest and disc diffusion to test the activity of trovafloxacin against Pseudomonas aeruginosa, methicillin-resistant Staphylococcus aureus and Streptococcus pneumoniae.
The Journal of antimicrobial chemotherapy 1999;43(5):707-9.
1999: Dianne B Hoellman; Gengrong Lin; Michael R Jacobs; Peter C Appelbaum
Anti-pneumococcal activity of gatifloxacin compared with other quinolone and non-quinolone agents.
The Journal of antimicrobial chemotherapy 1999;43(5):645-9.
1999: T Davies; Richard Goering; Marguerite Lovgren; James A Talbot; Michael R Jacobs; Peter C Appelbaum
Molecular epidemiological survey of penicillin-resistant Streptococcus pneumoniae from Asia, Europe, and North America.
Diagnostic microbiology and infectious disease 1999;34(1):7-12.
1999: Todd A Davies; Glenn A Pankuch; Bonifacio Dewasse; Michael R Jacobs; Peter C Appelbaum
In vitro development of resistance to five quinolones and amoxicillin-clavulanate in Streptococcus pneumoniae.
Antimicrobial agents and chemotherapy 1999;43(5):1177-82.
1999: Claudia K Hoyen; L Rice; S Conte; Michael R Jacobs; MC Walsh-Sukys; Philip Toltzis
Use of real time pulsed field gel electrophoresis to guide interventions during a nursery outbreak of Serratia marcescens infection.
The Pediatric infectious disease journal 1999;18(4):357-60.
1999: Michael R Jacobs
Assessing the quality of the Alexander Project.
Journal of chemotherapy (Florence, Italy) 1999;11 Suppl 1():26-34.
1999: Michael R Jacobs
Activity of quinolones against mycobacteria.
Drugs 1999;58 Suppl 2():19-22.
1999: Dianne B Hoellman; Gengrong Lin; Michael R Jacobs; Peter C Appelbaum
Activity of HMR 3647 compared to those of six compounds against 235 strains of Enterococcus faecalis.
Antimicrobial agents and chemotherapy 1999;43(1):166-8.
1998: Catherine L Clark; Michael R Jacobs; Peter C Appelbaum
Antipneumococcal activities of levofloxacin and clarithromycin as determined by agar dilution, microdilution, E-test, and disk diffusion methodologies.
Journal of clinical microbiology 1998;36(12):3579-84.
1998: Glenn A Pankuch; Dianne B Hoellman; G Lin; Saralee Bajaksouzian; Michael R Jacobs; Peter C Appelbaum
Activity of HMR 3647 compared to those of five agents against Haemophilus influenzae and moraxella catarrhalis by MIC determination and time-kill assay.
Antimicrobial agents and chemotherapy 1998;42(11):3032-4.
1998: Glenn A Pankuch; S A Jueneman; Todd A Davies; Michael R Jacobs; Peter C Appelbaum
In vitro selection of resistance to four beta-lactams and azithromycin in Streptococcus pneumoniae.
Antimicrobial agents and chemotherapy 1998;42(11):2914-8.
1998: Michael R Jacobs
Antibiotic-resistant Streptococcus pneumoniae in acute otitis media: overview and update.
The Pediatric infectious disease journal 1998;17(10):947-52.
1998: Lois M Ednie; Michael R Jacobs; Peter C Appelbaum
Activities of gatifloxacin compared to those of seven other agents against anaerobic organisms.
Antimicrobial agents and chemotherapy 1998;42(9):2459-62.
1998: MA Visalli; Michael R Jacobs; Peter C Appelbaum
Activities of three quinolones, alone and in combination with extended-spectrum cephalosporins or gentamicin, against Stenotrophomonas maltophilia.
Antimicrobial agents and chemotherapy 1998;42(8):2002-5.
1998: Glenn A Pankuch; Michael R Jacobs; Peter C Appelbaum
Postantibiotic effect of trovafloxacin against gram-positive and -negative organisms.
Antimicrobial agents and chemotherapy 1998;42(6):1503-5.
1998: Lois M Ednie; Michael R Jacobs; Peter C Appelbaum
Comparative activities of clinafloxacin against gram-positive and -negative bacteria.
Antimicrobial agents and chemotherapy 1998;42(5):1269-73.
1998: Glenn A Pankuch; Michael R Jacobs; Peter C Appelbaum
Antipneumococcal activity of grepafloxacin compared to that of other agents by time-kill methodology.
Antimicrobial agents and chemotherapy 1998;42(5):1263-5.
1998: SK Spangler; G Lin; Michael R Jacobs; Peter C Appelbaum
Postantibiotic effect and postantibiotic sub-MIC effect of levofloxacin compared to those of ofloxacin, ciprofloxacin, erythromycin, azithromycin, and clarithromycin against 20 pneumococci.
Antimicrobial agents and chemotherapy 1998;42(5):1253-5.
1998: MA Visalli; Michael R Jacobs; Peter C Appelbaum
Determination of activities of levofloxacin, alone and combined with gentamicin, ceftazidime, cefpirome, and meropenem, against 124 strains of Pseudomonas aeruginosa by checkerboard and time-kill methodology.
Antimicrobial agents and chemotherapy 1998;42(4):953-5.
1998: Dianne B Hoellman; MA Visalli; Michael R Jacobs; Peter C Appelbaum
Activities and time-kill studies of selected penicillins, beta-lactamase inhibitor combinations, and glycopeptides against Enterococcus faecalis.
Antimicrobial agents and chemotherapy 1998;42(4):857-61.
1998: Lois M Ednie; Michael R Jacobs; Peter C Appelbaum
Anti-anaerobic activity of erythromycin, azithromycin and clarithromycin: effect of pH adjustment of media to compensate for pH shift caused by incubation in CO2.
The Journal of antimicrobial chemotherapy 1998;41(3):387-9.
1998: Glenn A Pankuch; MA Visalli; Michael R Jacobs; Peter C Appelbaum
Susceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents.
Antimicrobial agents and chemotherapy 1998;42(3):624-30.
1998: Michael R Jacobs; R Dagan; Peter C Appelbaum; D J Burch
Prevalence of antimicrobial-resistant pathogens in middle ear fluid: multinational study of 917 children with acute otitis media.
Antimicrobial agents and chemotherapy 1998;42(3):589-95.
1998: Dianne B Hoellman; SK Spangler; Michael R Jacobs; Peter C Appelbaum
In vitro activities of cefminox against anaerobic bacteria compared with those of nine other compounds.
Antimicrobial agents and chemotherapy 1998;42(3):495-501.
1998: MA Visalli; Saralee Bajaksouzian; Michael R Jacobs; Peter C Appelbaum
Synergistic activity of trovafloxacin with other agents against gram-positive and -negative organisms.
Diagnostic microbiology and infectious disease 1998;30(1):61-4.
1998: Richard J Creger; K E Weeman; Michael R Jacobs; Anne M Morrissey; P Parker; Robert M Fox; Hillard M Lazarus
Lack of utility of the lysis-centrifugation blood culture method for detection of fungemia in immunocompromised cancer patients.
Journal of clinical microbiology 1998;36(1):290-3.
1998: Michael R Jacobs; Saralee Bajaksouzian; E L Palavecino-Fasola; H M Holoszyc; Peter C Appelbaum
Determination of penicillin MICs for Streptococcus pneumoniae by using a two- or three-disk diffusion procedure.
Journal of clinical microbiology 1998;36(1):179-83.
1997: N Venkataprasad; Michael R Jacobs; J L Johnson; Gilles Klopman; Jerrold Jay Ellner
Activity of new quinolones against intracellular Mycobacterium avium in human monocytes.
The Journal of antimicrobial chemotherapy 1997;40(6):841-5.
1997: MA Visalli; Michael R Jacobs; Peter C Appelbaum
Antipneumococcal activity of BAY 12-8039, a new quinolone, compared with activities of three other quinolones and four oral beta-lactams.
Antimicrobial agents and chemotherapy 1997;41(12):2786-9.
1997: S K Spangler; Gengrong Lin; Michael R Jacobs; Peter C Appelbaum
Postantibiotic effect of sanfetrinem compared with those of six other agents against 12 penicillin-susceptible and -resistant pneumococci.
Antimicrobial agents and chemotherapy 1997;41(10):2173-6.
1997: Lois M Ednie; Michael R Jacobs; Peter C Appelbaum
Comparative antianaerobic activities of the ketolides HMR 3647 (RU 66647) and HMR 3004 (RU 64004).
Antimicrobial agents and chemotherapy 1997;41(9):2019-22.
1997: MA Visalli; Michael R Jacobs; Peter C Appelbaum
Susceptibility of penicillin-susceptible and -resistant pneumococci to dirithromycin compared with susceptibilities to erythromycin, azithromycin, clarithromycin, roxithromycin, and clindamycin.
Antimicrobial agents and chemotherapy 1997;41(9):1867-70.
1997: MA Visalli; Michael R Jacobs; Peter C Appelbaum
Susceptibility of twenty penicillin-susceptible and -resistant pneumococci to levofloxacin, ciprofloxacin, ofloxacin, erythromycin, azithromycin, and clarithromycin by MIC and time-kill.
Diagnostic microbiology and infectious disease 1997;28(3):131-7.
1997: Michael R Jacobs; Saralee Bajaksouzian
Evaluation of Haemophilus influenzae isolates with elevated MICs to amoxicillin/clavulanic acid.
Diagnostic microbiology and infectious disease 1997;28(3):105-12.
1997: MA Visalli; Saralee Bajaksouzian; Michael R Jacobs; Peter C Appelbaum
Comparative activity of trovafloxacin, alone and in combination with other agents, against gram-negative nonfermentative rods.
Antimicrobial agents and chemotherapy 1997;41(7):1475-81.
1997: SK Spangler; Michael R Jacobs; Peter C Appelbaum
Time-kill study of the activity of trovafloxacin compared with ciprofloxacin, sparfloxacin, metronidazole, cefoxitin, piperacillin and piperacillin/tazobactam against six anaerobes.
The Journal of antimicrobial chemotherapy 1997;39 Suppl B():23-7.
1997: Michael R Jacobs
Respiratory tract infection: epidemiology and surveillance.
Journal of chemotherapy (Florence, Italy) 1997;9 Suppl 3():10-7.
1997: Saralee Bajaksouzian; MA Visalli; Michael R Jacobs; Peter C Appelbaum
Activities of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with amikacin, against acinetobacters as determined by checkerboard and time-kill studies.
Antimicrobial agents and chemotherapy 1997;41(5):1073-6.
1997: Lois M Ednie; SK Spangler; Michael R Jacobs; Peter C Appelbaum
Antianaerobic activity of the ketolide RU 64004 compared to activities of four macrolides, five beta-lactams, clindamycin, and metronidazole.
Antimicrobial agents and chemotherapy 1997;41(5):1037-41.
1997: Lois M Ednie; SK Spangler; Michael R Jacobs; Peter C Appelbaum
Susceptibilities of 228 penicillin- and erythromycin-susceptible and -resistant pneumococci to RU 64004, a new ketolide, compared with susceptibilities to 16 other agents.
Antimicrobial agents and chemotherapy 1997;41(5):1033-6.
1997: SK Spangler; Michael R Jacobs; Peter C Appelbaum
Bactericidal activity of DU-6859a compared to activities of three quinolones, three beta-lactams, clindamycin, and metronidazole against anaerobes as determined by time-kill methodology.
Antimicrobial agents and chemotherapy 1997;41(4):847-9.
1997: MA Visalli; Michael R Jacobs; T D Moore; F A Renzi; Peter C Appelbaum
Activities of beta-lactams against Acinetobacter genospecies as determined by agar dilution and E-test MIC methods.
Antimicrobial agents and chemotherapy 1997;41(4):767-70.
1997: S K Spangler; Michael R Jacobs; Peter C Appelbaum
Time-kill studies on susceptibility of nine penicillin-susceptible and -resistant pneumococci to cefditoren compared with nine other beta-lactams.
The Journal of antimicrobial chemotherapy 1997;39(2):141-8.
1997: SK Spangler; Michael R Jacobs; Peter C Appelbaum
MIC and time-kill studies of antipneumococcal activity of GV 118819X (sanfetrinem) compared with those of other agents.
Antimicrobial agents and chemotherapy 1997;41(1):148-55.
1997: E L Fasola; Saralee Bajaksouzian; Peter C Appelbaum; Michael R Jacobs
Variation in erythromycin and clindamycin susceptibilities of Streptococcus pneumoniae by four test methods.
Antimicrobial agents and chemotherapy 1997;41(1):129-34.
1996: E Fasola; SK Spangler; Lois M Ednie; Michael R Jacobs; Saralee Bajaksouzian; Peter C Appelbaum
Comparative activities of LY 333328, a new glycopeptide, against penicillin-susceptible and -resistant pneumococci.
Antimicrobial agents and chemotherapy 1996;40(11):2661-3.
1996: G Klopman; D Fercu; T E Renau; Michael R Jacobs
N-1-tert-butyl-substituted quinolones: in vitro anti-Mycobacterium avium activities and structure-activity relationship studies.
Antimicrobial agents and chemotherapy 1996;40(11):2637-43.
1996: Peter C Appelbaum; C Gladkova; Waleria Hryniewicz; B Kojouharov; D Kotulova; F Mihalcu; J Schindler; L Setchanova; N Semina; J Trupl; S Tyski; P Urbaskova; Michael R Jacobs
Carriage of antibiotic-resistant Streptococcus pneumoniae by children in eastern and central Europe--a multicenter study with use of standardized methods.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1996;23(4):712-7.
1996: Michael R Jacobs
Increasing importance of antibiotic-resistant Streptococcus pneumoniae in acute otitis media.
The Pediatric infectious disease journal 1996;15(10):940-3.
1996: Glenn A Pankuch; Michael R Jacobs; Peter C Appelbaum
MIC and time-kill study of antipneumococcal activities of RPR 106972 (a new oral streptogramin), RP 59500 (quinupristin-dalfopristin), pyostacine (RP 7293), penicillin G, cefotaxime, erythromycin, and clarithromycin against 10 penicillin-susceptible and -resistant pneumococci.
Antimicrobial agents and chemotherapy 1996;40(9):2071-4.
1996: Saralee Bajaksouzian; MA Visalli; Michael R Jacobs; Peter C Appelbaum
Antipneumococcal activities of cefpirome and cefotaxime, alone and in combination with vancomycin and teicoplanin, determined by checkerboard and time-kill methods.
Antimicrobial agents and chemotherapy 1996;40(9):1973-6.
1996: Lois M Ednie; MA Visalli; Michael R Jacobs; Peter C Appelbaum
Comparative activities of clarithromycin, erythromycin, and azithromycin against penicillin-susceptible and penicillin-resistant pneumococci.
Antimicrobial agents and chemotherapy 1996;40(8):1950-2.
1996: Hillard M Lazarus; Richard J Creger; Rasim Gucalp; R M Fox; N Ciobanu; P S Carlisle; Brenda W Cooper; Michael R Jacobs
Cefoperazone/sulbactam versus cefoperazone plus mezlocillin: empiric therapy for febrile, neutropenic bone marrow transplant patients.
International journal of antimicrobial agents 1996;7(2):85-91.
1996: Glenn A Pankuch; C Lichtenberger; Michael R Jacobs; Peter C Appelbaum
Antipneumococcal activities of RP 59500 (quinupristin-dalfopristin), penicillin G, erythromycin, and sparfloxacin determined by MIC and rapid time-kill methodologies.
Antimicrobial agents and chemotherapy 1996;40(7):1653-6.
1996: T T Kitch; Michael R Jacobs; M R McGinnis; Peter C Appelbaum
Ability of RapID Yeast Plus System to identify 304 clinically significant yeasts within 5 hours.
Journal of clinical microbiology 1996;34(5):1069-71.
1996: Hiroe Clerk Shiratsuchi; Michael R Jacobs; A J Pearson; N Venkataprasad; G Klopman; Jerrold Jay Ellner
Comparison of the activity of fluoroquinolones against Mycobacterium avium in cell-free systems and a human monocyte in-vitro infection model.
The Journal of antimicrobial chemotherapy 1996;37(3):491-500.
1996: SK Spangler; MA Visalli; Michael R Jacobs; Peter C Appelbaum
Susceptibilities of non-Pseudomonas aeruginosa gram-negative nonfermentative rods to ciprofloxacin, ofloxacin, levofloxacin, D-ofloxacin, sparfloxacin, ceftazidime, piperacillin, piperacillin-tazobactam, trimethoprim-sulfamethoxazole, and imipenem.
Antimicrobial agents and chemotherapy 1996;40(3):772-5.
1996: SK Spangler; Michael R Jacobs; Peter C Appelbaum
Activities of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin), two new oxazolidinones (U-100592 and U-100766), and other oral and parenteral agents against 203 penicillin-susceptible and -resistant pneumococci.
Antimicrobial agents and chemotherapy 1996;40(2):481-4.
1996: MA Visalli; Michael R Jacobs; Peter C Appelbaum
MIC and time-kill study of activities of DU-6859a, ciprofloxacin, levofloxacin, sparfloxacin, cefotaxime, imipenem, and vancomycin against nine penicillin-susceptible and -resistant pneumococci.
Antimicrobial agents and chemotherapy 1996;40(2):362-6.
1996: G Klopman; D Fercu; J Y Li; H S Rosenkranz; Michael R Jacobs
Antimycobacterial quinolones: a comparative analysis of structure-activity and structure-cytotoxicity relationships.
Research in microbiology 1996;147(1-2):86-96.
1996: MA Visalli; Michael R Jacobs; Peter C Appelbaum
Activity of CP 99,219 (trovafloxacin) compared with ciprofloxacin, sparfloxacin, clinafloxacin, lomefloxacin and cefuroxime against ten penicillin-susceptible and penicillin-resistant pneumococci by time-kill methodology.
The Journal of antimicrobial chemotherapy 1996;37(1):77-84.
1995: Glenn A Pankuch; MA Visalli; Michael R Jacobs; Peter C Appelbaum
Activities of oral and parenteral agents against penicillin-susceptible and -resistant pneumococci.
Antimicrobial agents and chemotherapy 1995;39(7):1499-504.
1995: John R Schreiber; Michael R Jacobs
Antibiotic-resistant pneumococci.
Pediatric clinics of North America 1995;42(3):519-37.
1995: SK Spangler; Michael R Jacobs; Peter C Appelbaum
Susceptibilities of 201 anaerobes to erythromycin, azithromycin, clarithromycin, and roxithromycin by oxyrase agar dilution and E test methodologies.
Journal of clinical microbiology 1995;33(5):1366-7.
1995: Michael R Jacobs
Activity of quinolones against mycobacteria.
Drugs 1995;49 Suppl 2():67-75.
1995: Glenn A Pankuch; Michael R Jacobs; Peter C Appelbaum
Activity of DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and OPC-17116 against 112 penicillin-susceptible and -resistant pneumococci.
Drugs 1995;49 Suppl 2():235-7.
1994: Glenn A Pankuch; Michael R Jacobs; Peter C Appelbaum
Susceptibilities of 200 penicillin-susceptible and -resistant pneumococci to piperacillin, piperacillin-tazobactam, ticarcillin, ticarcillin-clavulanate, ampicillin, ampicillin-sulbactam, ceftazidime, and ceftriaxone.
Antimicrobial agents and chemotherapy 1994;38(12):2905-7.
1994: SK Spangler; Michael R Jacobs; Peter C Appelbaum
In vitro susceptibilities of 185 penicillin-susceptible and -resistant pneumococci to WY-49605 (SUN/SY 5555), a new oral penem, compared with those to penicillin G, amoxicillin, amoxicillin-clavulanate, cefixime, cefaclor, cefpodoxime, cefuroxime, and cefdinir.
Antimicrobial agents and chemotherapy 1994;38(12):2902-4.
1994: SK Spangler; Michael R Jacobs; Peter C Appelbaum
Activity of WY-49605 compared with those of amoxicillin, amoxicillin-clavulanate, imipenem, ciprofloxacin, cefaclor, cefpodoxime, cefuroxime, clindamycin, and metronidazole against 384 anaerobic bacteria.
Antimicrobial agents and chemotherapy 1994;38(11):2599-604.
1994: SK Spangler; Michael R Jacobs; Peter C Appelbaum
Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes.
Antimicrobial agents and chemotherapy 1994;38(10):2471-6.
1994: Glenn A Pankuch; Michael R Jacobs; S F Rittenhouse; Peter C Appelbaum
Susceptibilities of 123 strains of Xanthomonas maltophilia to eight beta-lactams (including beta-lactam-beta-lactamase inhibitor combinations) and ciprofloxacin tested by five methods.
Antimicrobial agents and chemotherapy 1994;38(10):2317-22.
1994: Glenn A Pankuch; Michael R Jacobs; Peter C Appelbaum
Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology.
Antimicrobial agents and chemotherapy 1994;38(9):2065-72.
1994: G Klopman; J Y Li; Shaomeng Wang; A J Pearson; K Chang; Michael R Jacobs; Saralee Bajaksouzian; Jerrold Jay Ellner
In vitro anti-Mycobacterium avium activities of quinolones: predicted active structures and mechanistic considerations.
Antimicrobial agents and chemotherapy 1994;38(8):1794-802.
1994: A D Heggie; Michael R Jacobs; V T Butler; Jill Baley; B Boxerbaum
Frequency and significance of isolation of Ureaplasma urealyticum and Mycoplasma hominis from cerebrospinal fluid and tracheal aspirate specimens from low birth weight infants.
The Journal of pediatrics 1994;124(6):956-61.
1994: SK Spangler; Michael R Jacobs; Peter C Appelbaum
Susceptibilities of 177 penicillin-susceptible and -resistant pneumococci to FK 037, cefpirome, cefepime, ceftriaxone, cefotaxime, ceftazidime, imipenem, biapenem, meropenem, and vancomycin.
Antimicrobial agents and chemotherapy 1994;38(4):898-900.
1994: T T Kitch; Michael R Jacobs; Peter C Appelbaum
Evaluation of RapID onE system for identification of 379 strains in the family Enterobacteriaceae and oxidase-negative, gram-negative nonfermenters.
Journal of clinical microbiology 1994;32(4):931-4.
1994: Glenn A Pankuch; Michael R Jacobs; Peter C Appelbaum
Susceptibilities of 123 Xanthomonas maltophilia strains to clinafloxacin, PD 131628, PD 138312, PD 140248, ciprofloxacin, and ofloxacin.
Antimicrobial agents and chemotherapy 1994;38(2):369-70.
1994: SK Spangler; Michael R Jacobs; Peter C Appelbaum
Effect of CO2 on susceptibilities of anaerobes to erythromycin, azithromycin, clarithromycin, and roxithromycin.
Antimicrobial agents and chemotherapy 1994;38(2):211-6.
1994: Peter C Appelbaum; SK Spangler; Glenn A Pankuch; A Philippon; Michael R Jacobs; R Shiman; E J Goldstein; D M Citron
Characterization of a beta-lactamase from Clostridium clostridioforme.
The Journal of antimicrobial chemotherapy 1994;33(1):33-40.
1994: Peter C Appelbaum; SK Spangler; M Cohen; Michael R Jacobs
Comparison of the E-test and conventional agar dilution methods for susceptibility testing of gram-negative anaerobic rods.
Diagnostic microbiology and infectious disease 1994;18(1):25-30.
1993: S K Spangler; Michael R Jacobs; Peter C Appelbaum
Comparative activity of the new fluoroquinolone Bay y3118 against 177 penicillin susceptible and resistant pneumococci.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1993;12(12):965-7.
1993: M E Schricker; John R Schreiber; K Chiarucci; J Kerman; A Noe; Michael R Jacobs; B Berman
Absence of antibiotic-resistant Streptococcus pneumoniae pharyngeal colonization in Cleveland children with sickle cell disease.
The Pediatric infectious disease journal 1993;12(9):775-7.
1993: G Klopman; Shaomeng Wang; Michael R Jacobs; Jerrold Jay Ellner
Anti-Mycobacterium avium activity of quinolones: structure-activity relationship studies.
Antimicrobial agents and chemotherapy 1993;37(9):1807-15.
1993: G Klopman; Shaomeng Wang; Michael R Jacobs; Saralee Bajaksouzian; KL Edmonds; Jerrold Jay Ellner
Anti-Mycobacterium avium activity of quinolones: in vitro activities.
Antimicrobial agents and chemotherapy 1993;37(9):1799-806.
1993: Peter C Appelbaum; SK Spangler; Michael R Jacobs
Susceptibility of 539 gram-positive and gram-negative anaerobes to new agents, including RP59500, biapenem, trospectomycin and piperacillin/tazobactam.
The Journal of antimicrobial chemotherapy 1993;32(2):223-31.
1993: Glenn A Pankuch; Michael R Jacobs; Peter C Appelbaum
Susceptibilities of 428 gram-positive and -negative anaerobic bacteria to Bay y3118 compared with their susceptibilities to ciprofloxacin, clindamycin, metronidazole, piperacillin, piperacillin-tazobactam, and cefoxitin.
Antimicrobial agents and chemotherapy 1993;37(8):1649-54.
1993: D A Watkins; A Chahine; R J Creger; Michael R Jacobs; Hillard M Lazarus
Corynebacterium striatum: a diphtheroid with pathogenic potential.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1993;17(1):21-5.
1993: SK Spangler; Michael R Jacobs; Glenn A Pankuch; Peter C Appelbaum
Susceptibility of 170 penicillin-susceptible and penicillin-resistant pneumococci to six oral cephalosporins, four quinolones, desacetylcefotaxime, Ro 23-9424 and RP 67829.
The Journal of antimicrobial chemotherapy 1993;31(2):273-80.
1992: A D Heggie; Michael R Jacobs; P E Linz; D P Han; E L Kaplan; B Boxerbaum
Prevalence and characteristics of pharyngeal group A beta-hemolytic streptococci in US Navy recruits receiving benzathine penicillin prophylaxis.
The Journal of infectious diseases 1992;166(5):1006-13.
1992: Michael R Jacobs; SK Spangler; Peter C Appelbaum
beta-Lactamase production and susceptibility of US and European anaerobic gram-negative bacilli to beta-lactams and other agents.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1992;11(11):1081-93.
1992: Michael R Jacobs; Saralee Bajaksouzian; Peter C Appelbaum; A Bolmström
Evaluation of the E-Test for susceptibility testing of pneumococci.
Diagnostic microbiology and infectious disease 1992;15(5):473-8.
1992: Michael R Jacobs
Treatment and diagnosis of infections caused by drug-resistant Streptococcus pneumoniae.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1992;15(1):119-27.
1992: T T Kitch; Michael R Jacobs; Peter C Appelbaum
Evaluation of the 4-hour RapID NF Plus method for identification of 345 gram-negative nonfermentative rods.
Journal of clinical microbiology 1992;30(5):1267-70.
1992: Peter C Appelbaum; SK Spangler; R Shiman; Michael R Jacobs
Susceptibilities of 540 anaerobic gram-negative bacilli to amoxicillin, amoxicillin-BRL 42715, amoxicillin-clavulanate, temafloxacin, and clindamycin.
Antimicrobial agents and chemotherapy 1992;36(5):1140-3.
1992: SK Spangler; Michael R Jacobs; Peter C Appelbaum
Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin, and ciprofloxacin.
Antimicrobial agents and chemotherapy 1992;36(4):856-9.
1991: Michael R Jacobs
Evaluation of the bactericidal activity of temafloxacin.
The American journal of medicine 1991;91(6A):31S-34S.
1991: Peter C Appelbaum; SK Spangler; Michael R Jacobs
Susceptibilities of 394 Bacteroides fragilis, non-B. fragilis group Bacteroides species, and Fusobacterium species to newer antimicrobial agents.
Antimicrobial agents and chemotherapy 1991;35(6):1214-8.
1990: Michael R Jacobs; SK Spangler; Peter C Appelbaum
Beta-lactamase production, beta-lactam sensitivity and resistance to synergy with clavulanate of 737 Bacteroides fragilis group organisms from thirty-three US centres.
The Journal of antimicrobial chemotherapy 1990;26(3):361-70.
1990: Peter C Appelbaum; S K Spangler; Michael R Jacobs
Beta-lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-Bacteroides fragilis Bacteroides isolates and 129 fusobacteria from 28 U.S. centers.
Antimicrobial agents and chemotherapy 1990;34(8):1546-50.
1990: Michael R Jacobs; SK Spangler; Peter C Appelbaum
Susceptibility of Bacteroides non-fragilis and fusobacteria to amoxicillin, amoxicillin/clavulanate, ticarcillin, ticarcillin/clavulanate, cefoxitin, imipenem and metronidazole.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1990;9(6):417-21.
1990: Jill Baley; C Meyers; R M Kliegman; Michael R Jacobs; J L Blumer
Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates.
The Journal of pediatrics 1990;116(5):791-7.
1990: Peter C Appelbaum; SK Spangler; Michael R Jacobs
Evaluation of two methods for rapid testing for beta-lactamase production in Bacteroides and Fusobacterium.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1990;9(1):47-50.
1989: Michael R Jacobs; Stephen C. Aronoff; Peter C Appelbaum; S Yamabe
In vitro activity of YTR 830.
Journal of chemotherapy (Florence, Italy) 1989;1(3):151-4.
1989: Peter C Appelbaum; SK Spangler; E Crotty; Michael R Jacobs
Susceptibility of penicillin-sensitive and -resistant strains of Streptococcus pneumoniae to new antimicrobial agents, including daptomycin, teicoplanin, cefpodoxime and quinolones.
The Journal of antimicrobial chemotherapy 1989;23(4):509-16.
1988: A Raja; A R Machicao; Anne M Morrissey; Michael R Jacobs; Thomas M Daniel
Specific detection of Mycobacterium tuberculosis in radiometric cultures by using an immunoassay for antigen 5.
The Journal of infectious diseases 1988;158(2):468-70.
1988: B Boxerbaum; Michael R Jacobs; R L Cechner
Prevalence and significance of methicillin-resistant Staphylococcus aureus in patients with cystic fibrosis.
Pediatric pulmonology 1988;4(3):159-63.
1987: Stephen C. Aronoff; M M Olson; Michael W L Gauderer; Michael R Jacobs; J L Blumer; R J Izant
Pseudomonas aeruginosa as a primary pathogen in children with bacterial peritonitis.
Journal of pediatric surgery 1987;22(9):861-4.
1987: P M Wiest; K Wiese; Michael R Jacobs; Anne M Morrissey; T I Abelson; W Witt; Michael M Lederman
Alternaria infection in a patient with acquired immunodeficiency syndrome: case report and review of invasive alternaria infections.
Reviews of infectious diseases 1987;9(4):799-803.
1986: Stephen C. Aronoff; Michael R Jacobs; P H Labrozzi; S Yamabe
Synergy of amoxycillin combined with clavulanate and YTR 830 in experimental infections in mice.
The Journal of antimicrobial chemotherapy 1986;18(2):271-6.
1986: Michael R Jacobs; Stephen C. Aronoff; S Johenning; S Yamabe
Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate and sulbactam combined with extended-spectrum penicillins against ticarcillin-resistant Enterobacteriaceae and pseudomonads.
The Journal of antimicrobial chemotherapy 1986;18(2):177-84.
1986: Michael R Jacobs; Stephen C. Aronoff; S Johenning; D M Shlaes; S Yamabe
Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined beta-lactamase-producing aerobic gram-negative bacilli.
Antimicrobial agents and chemotherapy 1986;29(6):980-5.
1984: Stephen C. Aronoff; Michael R Jacobs; S Johenning; S Yamabe
Comparative activities of the beta-lactamase inhibitors YTR 830, sodium clavulanate, and sulbactam combined with amoxicillin or ampicillin.
Antimicrobial agents and chemotherapy 1984;26(4):580-2.